Adaptimmune ‘Neck And Neck’ For First Solid Tumor T-Cell Therapy Nod For Afami-Cel
Company Looks Beyond Small Sarcoma Market For Afamitresgene Autoleucel
The company’s CEO and chief medical officer talked about some challenges as well as opportunities and what they have learned from the experience of other cell therapies.
You may also be interested in...
An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.
In this week's podcast edition of Five Must-Know Things: a preview of the ASCO meeting; small biopharma companies thrive in the US; the world’s first positive Phase III data for a microbiome therapy; Adaptimmune’s plans for its T-cell receptor therapy; and Novo looks at semaglutide in early Alzheimer’s.
Iovance has a promising new cancer cell therapy on its hands, but another FDA query and the CEO’s departure has spooked investors.